Loading...
  • antigens
  • This vaccine format elicits B and T cell-dependent protection and targets multiple antigens, including the highly conserved viral nucleoprotein, indicating its usefulness as a cross-protective vaccine. (typepad.com)
  • Developing this chlamydia vaccine, along with the unique method that we have for making these antigens "on-demand" or as needed for use in vaccines, could be a godsend for the epidemic that's affecting the koalas, and also obviously has implications for treatment of diseases that affect humans as well-it's not just chlamydia, there's a whole host of disease antigens that are notoriously difficult to produce," He added. (phys.org)
  • However, recent improvements in our understanding of the immune responses required to combat each stage of infection will allow for intelligent design of both antigens and their associated delivery vaccine vehicles/vectors. (mdpi.com)
  • In this Phase I project, we will use an innovative approach to produce synthetic nanoparticle vaccines carrying the RSV-G peptide coupled with RSV T-cell target antigens that favor IFN responses. (grantome.com)
  • particles
  • Selecta Biosciences Inc., a clinical stage biotechnology company that is developing an innovative class of targeted antigen-specific immune therapies with synthetic vaccine particles (SVPs), recently announced that SVP may be crucial to developing an innovative vaccine technology targeting mucosal tissues. (vaccinenewsdaily.com)
  • Watertown, Mass. - December 23, 2014 - Selecta Biosciences, a clinical-stage biotechnology company developing novel drugs that use immune-modulating nanomedicines based on Synthetic Vaccine Particles (SVP™), announced today that it has been awarded a $3.2 Million grant from Skolkovo Foundation in support of Selecta's program to develop an SVP immunotherapy to treat cancers caused by infections with Human Papilloma Virus (HPV), such as cervical, head and neck cancers. (selectabio.com)
  • In a recent milestone development under Blue Angel, researchers at Medicago Inc. produced more than 10 million doses (as defined in an animal model) of an H1N1 influenza vaccine candidate based on virus-like particles (VLP) in one month. (blogspot.com)
  • efficacy
  • Selecta's proprietary Synthetic Vaccine Particle ( SVP ) platform creates a novel paradigm in immunotherapeutics and vaccines, enabling completely new applications while offering the potential of improved efficacy and safety profiles. (businesswire.com)
  • The synthetic peptide vaccine developed by the University of Pittsburgh has previously demonstrated single-agent clinical efficacy, including complete responses (CRs), in Phase 1/2 trials in both adults and children with high-grade glioma (HGG), including glioblastoma multiforme (GBM). (cnbc.com)
  • The deliverable of this project is one or more LbL RSV-G vaccine candidates with demonstrated safety and efficacy in animal models;these candidates will be further developed in a subsequent Phase II project that will complete the steps necessary for Investigational New Drug application filing and eventual clinical testing. (grantome.com)
  • Inadequate stimulation of the neonatal immune system and the requirement for multiple booster administrations have limited the efficacy of the majority of current vaccine formulations. (northwestern.edu)
  • Furthermore, the current global shortage in BCG calls attention to the current lack of scalable synthetic formulations that can achieve similar and potentially improved efficacy relative to immunization with live attenuated pathogens. (northwestern.edu)
  • peptides
  • SL-701 is a subcutaneously-administered cancer vaccine comprised of multiple synthetic peptides corresponding to targets on tumor bulk and cancer stem cells (CSCs). (cnbc.com)
  • The P53-SLP vaccine is a vaccine consisting of a total of 10 long (30 amino acids on average length) peptides, covering the p53 protein sequence from amino acid 70 to 251, combined with Montanide ISA51 an adjuvant with a sustained dendritic cell activating ability. (clinicaltrials.gov)
  • 2017
  • San Diego, Calif., October 31, 2017 - Arcturus Therapeutics, Inc., a leading RNA medicines company, and Synthetic Genomics, Inc. announced today that they have entered into a research collaboration and worldwide license agreement to develop self-amplifying RNA-based vaccines and therapeutics in both human and animal health. (syntheticgenomics.com)
  • The report also presents forecasts for Synthetic Peptide Vaccine investments from 2017 till 2022. (equityinsider.org)
  • protein
  • When they tested their vaccine in mice with HPV16-induced tumours, they found that TriVax containing a small synthetic fragment (peptide) of the E7 protein "induced tumour clearance in 100 percent of the treated mice" while the unvaccinated mice with HPV-induced tumours had their tumours grow "at a fast rate. (compamed-tradefair.com)
  • Cell- Free Production of a Functional Oligomeric Form of a Chlamydia Major Outer Membrane Protein (MOMP) for Vaccine Development. (phys.org)
  • Synthetic Genomics' RNA replicons provide the genetic instructions to the body's own cells to produce ample amounts of protein and unleash a powerful immune response. (syntheticgenomics.com)
  • Building on a previous DARPA program, Accelerated Manufacture of Pharmaceuticals, Blue Angel targets new ways of producing large amounts of high quality, vaccine grade protein in less than three months in response to emerging and novel biological threats. (blogspot.com)
  • Therefore, in a continuing effort towards designing economical and potent vaccine candidates, the current study applied yeast surface display technology to develop an oral dengue vaccine candidate using whole recombinant yeast cells displaying the recombinant fusion protein of M cell targeting ligand Co1 fused to the synthetic consensus dengue envelope domain III (scEDIII). (springer.com)
  • Plasmodium vivax circumsporozoite (CS) protein is a leading malaria vaccine candidate previously assessed in animals and humans. (ajtmh.org)
  • mice
  • The scientists administered the vaccine or placebo to mice and a booster vaccine two weeks later. (medicalxpress.com)
  • Using synthetic messenger RNA (mRNA) instead of proteins purified from viruses, German scientists have shown they can protect mice, ferrets, and pigs against influenza. (blogspot.com)
  • We have previously described a microsphere-based CTL vaccine platform capable of eliciting an immune response for class I epitopes in mice and are currently working toward in vivo testing of class I and class II epitope delivery directed against ZKV epitopes using the same microsphere-based vaccine. (frontiersin.org)
  • BALB/c mice and Aotus monkeys were divided into test and control groups and were immunized three times with doses of 50 and 100 μg of vaccine or placebo. (ajtmh.org)
  • traditional vaccines
  • Traditional vaccines and approaches have not been effective in treating many of the serious and chronic infectious diseases that survive in mucosa. (vaccinenewsdaily.com)
  • For the case of Chlamydia, we now have a mechanistic explanation for the failure of traditional vaccines combined with an SVP-based vaccination strategy that can overcome these challenges and create a vaccine with the potential to engender the desired robust immunoprotection. (vaccinenewsdaily.com)
  • Unlike traditional vaccines, there is no chance that the empty shell vaccine could revert to an infectious form," said Dave Stuart, Life Sciences Director at Diamond, and MRC Professor of Structural Biology at the University of Oxford in an article on the BBC website . (vaccinenation.org)
  • novel
  • The overarching goals of this approach are to limit the number of vaccine reformulations that can be deployed to protect against novel H3N2 viruses. (medicalxpress.com)
  • In addition to designing novel organisms that overcome fundamental hurdles of scientific research and medicine, Synthetic Genomics pursues partnerships with organizations seeking to dramatically improve upon existing products in health care, energy and other sectors. (syntheticgenomics.com)
  • This project will use an innovative nanoparticle technology to produce novel vaccine candidates for respiratory syncytial virus. (grantome.com)
  • Therapeutics
  • The collaboration will bring together Arcturus's LUNAR™ lipid-mediated delivery platform with Synthetic Genomics' RNA replicon platform to potentially enable more efficacious and lower cost vaccines and therapeutics. (syntheticgenomics.com)
  • Under the collaboration, Synthetic Genomics will have exclusive access to LUNAR technology for vaccines and therapeutics, using self-amplifying RNA. (syntheticgenomics.com)
  • This collaboration gives us the opportunity to apply our LUNAR technology to address unmet needs in both vaccines and therapeutics. (syntheticgenomics.com)
  • We have made tremendous progress in programming our replicon RNA system to develop next generation vaccines and therapeutics," said Oliver Fetzer, Ph.D., chief executive officer of Synthetic Genomics. (syntheticgenomics.com)
  • Thus
  • Thus, there is a need to develop therapeutic vaccines for HPV-related tumours. (compamed-tradefair.com)
  • Since there is a risk of insufficient response and thus inadequate protection against infections in patients on DMARDs," Dr. Kapetanovic advises, "our results suggest that pneumococcal vaccine should preferably be administered before the start of such treatments. (the-rheumatologist.org)
  • therapeutic
  • Combining Synthetic Genomics' replicons with Arcturus' LUNAR technology may enable the replicon RNA to avoid degradation and target the tissues and cell types needed to promote a protective immune response or drive expression of therapeutic proteins. (syntheticgenomics.com)
  • Genomics
  • Synthetic Genomics, Inc. (syntheticgenomics.com)
  • This agreement with Synthetic Genomics is in line with our corporate strategy to form strategic collaborations that leverage our proprietary technologies," said Joseph Payne, president and chief executive officer of Arcturus. (syntheticgenomics.com)
  • About Synthetic Genomics, Inc. (syntheticgenomics.com)
  • Synthetic Genomics is programming the operating system of life to create sustainable solutions for humankind's most pressing issues, from the wellbeing of our population to the health of our planet. (syntheticgenomics.com)
  • With an unmatched understanding of how DNA drives the function of cells - the basic biological units of all living organisms - Synthetic Genomics modifies and writes genomes to enable transformative products in the areas of vaccines, medicines, nutrition, and biotechnology research. (syntheticgenomics.com)
  • Continuing its legacy of scientific firsts in genomics and synthetic biology, Synthetic Genomics is harnessing the power of nature to improve quality of life. (syntheticgenomics.com)
  • approaches
  • Current vaccine design and manufacturing to meet the antigenic diversity of H3N2 viruses is challenging, and with another flu season approaching there remains a pressing need for new vaccine approaches for influenza," said lead researcher David B. Weiner, Ph.D., executive vice president and director of the Vaccine & Immunotherapy Center at The Wistar Institute, and W.W. Smith Charitable Trust Professor in Cancer Research. (medicalxpress.com)
  • The self-amplifying RNA triggers rapid and immediate antigen expression within host cells, stronger T-cell response (including when the host is already infected), and lower dose requirements compared to traditional RNA-based vaccine approaches. (syntheticgenomics.com)
  • vectors
  • Synthetic carriers (also known as vectors) are usually particulate and have multiple properties, which can be varied to control how an associated vaccine interacts with the host, and consequently how the immune response develops. (mdpi.com)
  • development
  • Advanced genetic engineering is already changing vaccine development and could make inroads into other branches of medicine. (technologyreview.com)
  • New horizons in adjuvants for vaccine development. (naver.com)
  • The application of this innovative approach to RSV vaccine development will also impact vaccine development for other infectious diseases. (grantome.com)
  • Address correspondence to Sócrates Herrera, Malaria Vaccine and Drug Development Center, Carrera 37 - 2Bis No. 5E - 08, Cali, Colombia. (ajtmh.org)
  • This work will have a broad and enduring impact on vaccine development, and the technology should be transferable to other viruses from the same family, such as poliovirus and hand-foot-and-mouth disease, a human virus which is currently endemic in South-East Asia. (vaccinenation.org)
  • mucosal
  • Consistent with our company's strategy for infectious disease indications, we will actively seek value-adding partners with whom to develop and commercialize SVP for mucosal vaccines. (vaccinenewsdaily.com)
  • Chlamydia
  • There are several examples where conventional vaccines exacerbated infections in human clinical trials, including Chlamydia and RSV," Dr. Ulrich von Andrian, Mallinckrodt Professor of Immunopathology at Harvard Medical School and the co-founder of Selecta, said. (vaccinenewsdaily.com)
  • A multidisciplinary scientific team at Lawrence Livermore National Laboratory (LLNL) has made significant advances in developing a vaccine for chlamydia using synthetic biology, sponsored by a two-year National Institutes of Health (NIH ) grant. (phys.org)
  • Furthermore
  • Furthermore, the requirements for a synthetic carrier, such as size, charge, and surface chemistry are reviewed in order to understand the design of effective particle-based vaccines against malaria, as well as providing general insights. (mdpi.com)
  • proteins
  • The TriVax vaccine strategy was designed to generate large numbers of cytotoxic T-cells that would seek out the proteins preferentially expressed in the tumours. (compamed-tradefair.com)
  • In other work described at the Cambridge meeting, Pam Silver , a synthetic biologist at Harvard Medical School, presented methods for "cell-based computing," in which logic gates can be built from engineered proteins. (technologyreview.com)
  • adults
  • Based on these results, Stemline, who licensed patent rights relating to the Pitt vaccine from the University of Pittsburgh, is planning registration-directed programs in both adults and children with HGG. (cnbc.com)
  • unmet
  • A vaccine emerging from this effort will address a large unmet need in infants, children, elderly and immunocompromised patients. (grantome.com)
  • develop
  • WATERTOWN, Mass.--( BUSINESS WIRE )-- Selecta Biosciences, Inc. , and JDRF , announced today that they have extended their joint research collaboration and attracted Sanofi as a partner in support of their program to develop a Synthetic Vaccine Particle (SVP™) immunotherapy with the long-term goal to treat and potentially prevent the underlying cause of type 1 diabetes. (businesswire.com)
  • Early attempts to develop a formalin- inactivated vaccine (FI-RSV) resulted in disease enhancement following environmental exposure to RSV. (grantome.com)
  • Develop a synthetic platform to support vaccination against diverse pathogens at birth by mimicking the molecular composition and release kinetics of BCG. (northwestern.edu)
  • therapies
  • Vaccines for cancer can be good alternatives to conventional therapies that result in serious side-effects and are rarely effective against advanced disease," said Doctor Esteban Celis. (compamed-tradefair.com)
  • viruses
  • Current vaccine production based on inactivated viruses (live attenuated vaccines), has been successful in reducing significant disease burden associated with major epidemics of the 19th and 20th centuries. (blogspot.com)
  • analyzes
  • This review comprehensively analyzes both historical and recent studies in which synthetic carriers are used to deliver malaria vaccines. (mdpi.com)
  • Secondly the study, besides estimating the Synthetic Peptide Vaccine market potential till 2022, analyzes on who can be the market leaders and what partnerships would help them to capture the market share. (equityinsider.org)
  • research
  • To sum it up, the report concludes with an all-inclusive research result on the industry chain of Synthetic Peptide Vaccine Sales Industry facilitating the market participants in making well-informed strategic decisions. (beforeitsnews.com)
  • Malaria vaccine research has been ongoing since the 1980s with limited success. (mdpi.com)
  • We're looking at plant based solutions to vaccine production as a more rapid and efficient alternative to the standard egg-based technologies, and the research is very promising. (blogspot.com)